


Connect to the numbers

Latest funding figures as at 31 March 2023

The graphic below shows how the balance between the assets (the value of the Fund's investments) and the liabilities (the cost of providing members' benefits) has developed since the figures we reported in April 2022. These pages cover the headlines of the latest full Actuarial Valuation as at 31 March 2022 and the interim check carried out in 2023.



Funding improved further in the year to 31 March 2023 as rises in gilt yields reduced the value of the liabilities. As a proportion of the Fund's assets are invested in such a way to broadly match movements in the Fund's liabilities, this also led to a fall in the value of the assets. The funding gap decreased between 2021 and 2022 due to extra contributions being paid by AstraZeneca and positive investment performance by which assets grew by more than liabilities.

Filling the funding gap

As part of the full 2022 Valuation, the Trustee and the Company have agreed a plan to close the funding gap of £347 million. The Company will continue to pay contributions of £39 million a year to the Fund until 2028 under this plan.

How was the Fund affected by the ‘bond crisis’ in late-2022?

UK bond markets experienced extreme volatility in the final few months of 2022. During this time, the Trustee was actively monitoring the risks from the Fund’s bond investments. We worked closely with our advisers to ensure that the Fund was able to manage these appropriately. This process worked well and the Fund remained stable in its funding position during the ‘bond crisis’ (unlike some other UK pension plans).

By law, we need to tell you:

- If the Fund had been wound up on 31 March 2022, its assets at that date would have covered 73.3% of the estimated amount needed to buy members’ full benefits from an insurance company. AstraZeneca has no plans to wind up the Fund.
- The Pensions Regulator has not modified the Fund nor imposed any directions, or Schedule of Contributions.
- There have not been any payments from the Fund to the Company since the last statement.

Reporting on the Fund investments with climate change in mind

The Trustee has recently published its first report on the Fund’s risks and investment policy in relation to climate change scenarios and its general policies to reduce the Fund’s carbon consumption directly and indirectly (the Task Force on Climate-related Financial Disclosures (TCFD) Report). You can find it at: epa.towerswatson.com/accounts/astrazeneca